Edward Carraway, MD
Interventional Cardiology · Tuscaloosa, ALNPI 1114139300
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 588 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by Novartis at 27.9% of the total. Reporting peaked in 2019 at $2,284 and has fallen 70.1% since, to $683 in 2025.
Across 588 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Johnson & Johnson$740
- Amgen$563
- Abbott$377
- Sanofi-aventis U.S. LLC$333
- plus $3K from 33 others
What the payments were for
- Food & beverage$8,390100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 228 | $2,344 |
| Actelion Pharmaceuticals US, Inc. | 86 | $1,312 |
| Johnson & Johnson | 59 | $740 |
| Amgen | 44 | $563 |
| Abbott | 15 | $377 |
| Sanofi-aventis U.S. LLC | 19 | $333 |
| Angiodynamics, Inc. | 4 | $275 |
| Medtronic(2 entities) | 5 | $255 |
| Philips North America LLC | 8 | $222 |
| United Therapeutics Corporation | 16 | $185 |
| Novo Nordisk | 8 | $169 |
| Gilead | 12 | $155 |
| Bard Peripheral Vascular, Inc. | 5 | $148 |
| Boehringer Ingelheim | 7 | $137 |
| Amarin Pharma, Inc. | 9 | $131 |
| Pfizer | 8 | $122 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $118 |
| Merck | 5 | $102 |
| Lundbeck LLC | 4 | $97 |
| AstraZeneca | 6 | $76 |
| Bayer | 5 | $74 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| Chiesi USA, Inc. | 4 | $64 |
| Cardiovascular Systems Inc. | 3 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Inari Medical, Inc. | 2 | $39 |
| Convatec Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Cleerly, Inc. | 1 | $19 |
| GSK | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Shockwave Medical, Inc | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Akcea Therapeutics, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT Devices Und$123
- SYMPLICITY G3$115
How this compares
$8,408 in reported general payments places this provider in the 60th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 53 | $670,023 |
| EliquisApixaban | 493 | $427,679 |
| Ambrisentan | 21 | $107,201 |
| XareltoRivaroxaban | 115 | $100,926 |
| CamzyosMavacamten | 12 | $94,765 |
| EntrestoSacubitril/Valsartan | 67 | $82,573 |
| MultaqDronedarone Hcl | 60 | $71,248 |
| JardianceEmpagliflozin | 35 | $41,369 |
| Repatha SureclickEvolocumab | 30 | $28,097 |
| BrilintaTicagrelor | 33 | $18,731 |
| FarxigaDapagliflozin Propanediol | 15 | $13,155 |
| Metoprolol Succinate | 465 | $9,651 |
| Tadalafil | 12 | $8,224 |
| Ranolazine ErRanolazine | 73 | $7,822 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 22 | $4,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,312 | $670,02353 claims |
| PfizerEliquis | $122 | $427,679493 claims |
| Johnson & JohnsonXarelto | $740 | $100,926115 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $12 | $94,76512 claims |
| NovartisEntresto | $2,344 | $82,57367 claims |
| Sanofi-aventis U.S. LLCMultaq | $333 | $71,24860 claims |
| Boehringer IngelheimJardiance | $137 | $41,36935 claims |
| AstraZenecaBrilinta, Farxiga | $76 | $31,88648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Tuscaloosa
- George HemstreetTuscaloosa$35K
- William HillTuscaloosa$7K
- Lovdie LewisTuscaloosa$6K
- James ProctorTuscaloosa$6K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.